[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3534 followers Created: 2025-07-21 11:03:38 UTC Stifel reiterated $ALKS Buy-$42 and said, "We are reiterating our Buy rating on $ALKS on the back of positive top-line data for ALKS2680/"Alixorexton" in Narcolepsy Type-1." $TAK $BIIB $AXSM $JAZZ $CNTA Stifel added, "Bottom line: this study was widely expected to succeed given prior ph1b data in NT1 and broader support via Takeda. Even still, the results here look clearly positive with many key clinical endpoints hitting statistical significance at all doses, with the exception of cataplexy attacks which "numerically improved" at all doses and only hit a p-value at the mid-dose (we await details, but probably a powering/variability issue). On safety, the disclosure was fairly high level, but XX% of patients who participated in the trial entered the OLE which is always encouraging. The PR specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams, but we'll need to wait for full data to see if there were any mild visual AEs at all -- we remain generally unconcerned though." XXXXX engagements  **Related Topics** [$cnta](/topic/$cnta) [$biib](/topic/$biib) [$tak](/topic/$tak) [$alks](/topic/$alks) [biogen inc](/topic/biogen-inc) [stocks healthcare](/topic/stocks-healthcare) [$axsm](/topic/$axsm) [$jazz](/topic/$jazz) [Post Link](https://x.com/Quantumup1/status/1947251115277353101)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3534 followers
Created: 2025-07-21 11:03:38 UTC
Stifel reiterated $ALKS Buy-$42 and said, "We are reiterating our Buy rating on $ALKS on the back of positive top-line data for ALKS2680/"Alixorexton" in Narcolepsy Type-1." $TAK $BIIB $AXSM $JAZZ $CNTA Stifel added, "Bottom line: this study was widely expected to succeed given prior ph1b data in NT1 and broader support via Takeda. Even still, the results here look clearly positive with many key clinical endpoints hitting statistical significance at all doses, with the exception of cataplexy attacks which "numerically improved" at all doses and only hit a p-value at the mid-dose (we await details, but probably a powering/variability issue). On safety, the disclosure was fairly high level, but XX% of patients who participated in the trial entered the OLE which is always encouraging.
The PR specifically noted no treatment-related signals in hepatic/renal parameters, vital signs or ophthalmic exams, but we'll need to wait for full data to see if there were any mild visual AEs at all -- we remain generally unconcerned though."
XXXXX engagements
Related Topics $cnta $biib $tak $alks biogen inc stocks healthcare $axsm $jazz